RLYB
RLYB clinical trials: Rallybio Corp
Every trial on ClinicalTrials.gov where Rallybio Corp is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 3
- Trials linked
- 3
- As lead sponsor
- 0
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
RLYB on the catalyst calendar · RLYB registry changes
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Jan 31, 2025Actual | NCT05345561Study to Assess the Occurrence of HPA-1a Alloimmunization in Women With Higher Risk for Fetal and Neonatal Alloimmune ThrombocytopeniaRallybio · Fetal and Neonatal Alloimmune Thrombocytopenia | RLYBLead | No phase registered | Completed | Locked | Locked | Locked |
| Oct 1, 2025Actual | NCT06435845Phase 2 Study on the Pharmacokinetics and Safety of RLYB212 in Pregnant Women at Higher Risk for HPA-1a AlloimmunizationRallybio · Fetal and Neonatal Alloimmune Thrombocytopenia | RLYBLead | Phase 2 | Terminated | Locked | Locked | Locked |
| Feb 9, 2026Actual | NCT06797375Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of RLYB116 in Healthy ParticipantsRallybio · Hematologic Diseases | RLYBLead | Phase 1 | Completed | Locked | Locked | Locked |
- Primary completion Jan 31, 2025ActualNo phase registeredNCT05345561Study to Assess the Occurrence of HPA-1a Alloimmunization in Women With Higher Risk for Fetal and Neonatal Alloimmune ThrombocytopeniaRallybio · Fetal and Neonatal Alloimmune ThrombocytopeniaCompletedRLYBLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 1, 2025ActualPhase 2NCT06435845Phase 2 Study on the Pharmacokinetics and Safety of RLYB212 in Pregnant Women at Higher Risk for HPA-1a AlloimmunizationRallybio · Fetal and Neonatal Alloimmune ThrombocytopeniaTerminatedRLYBLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 9, 2026ActualPhase 1NCT06797375Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of RLYB116 in Healthy ParticipantsRallybio · Hematologic DiseasesCompletedRLYBLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 3 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner